Abstract Number: 1957 • ACR Convergence 2024
Assessing Left Ventricular Hemodynamic Forces in Systemic Sclerosis Patients: Pilot Study
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease marked by inflammation, microvascular changes and fibrosis. Cardiac comorbidities are the leading cause of mortality. Early…Abstract Number: 0417 • ACR Convergence 2024
Contraception in Community Rheumatology Practices
Background/Purpose: Most prior studies of contraception in women with rheumatic disease focused on academic centers. In this study of non-academic rheumatology practices, we sought to…Abstract Number: 1958 • ACR Convergence 2024
Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients
Background/Purpose: Cardiac sarcoidosis (CS) is an underdiagnosed condition characterized by the formation of non-caseating granuloma in the myocardium, potentially leading to arrhythmia, acute heart failure,…Abstract Number: 0446 • ACR Convergence 2024
Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
Background/Purpose: Methotrexate (MTX) and mycophenolate (MMF) are two common medications for both lupus (SLE) and rheumatoid arthritis (RA). Both medications are contraindicated in pregnancy, necessitating…Abstract Number: 2096 • ACR Convergence 2024
A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI
Background/Purpose: There is a need to design models that predict the risk of total joint replacement (TJR) in patients with knee osteoarthritis (OA). Our aim…Abstract Number: 0133 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study
Background/Purpose: COVID-19 vaccines have been proven to be safe in healthy populations. However, data on delayed adverse effects (AEs) in people with autoimmune diseases (AIDs),…Abstract Number: 1097 • ACR Convergence 2023
Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at increased risk of infection. The Centers for Disease Control and Prevention (CDC) and the ACR strongly…Abstract Number: 2558 • ACR Convergence 2023
Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab
Background/Purpose: Aortic aneurysms is a serious complication that can occur in patients with giant cell arteritis (GCA) (1-2). Tocilizumab (TCZ) is approved for GCA. Nevertheless,…Abstract Number: 0198 • ACR Convergence 2023
Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership
Background/Purpose: Herpes zoster (HZ), also known as shingles, causes an estimated one million cases annually in the United States. Many studies have shown that the…Abstract Number: 1099 • ACR Convergence 2023
Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases. To minimize the risk of retinal toxicity, the American College…Abstract Number: 2581 • ACR Convergence 2023
Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…Abstract Number: 0203 • ACR Convergence 2023
Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…Abstract Number: 1351 • ACR Convergence 2023
HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center
Background/Purpose: Adolescent and young adults (AYAs) with rheumatic disease (RD) may face disproportionate risk of HPV and associated cancers due to immune dysregulation, immunosuppression and…Abstract Number: 2584 • ACR Convergence 2023
Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…Abstract Number: 0208 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients. Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »